+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction



Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction



Respiratory Research 16: 34



The demographics of patients with idiopathic pulmonary arterial hypertension (IPAH) are changing and this diagnosis is increasingly being made in older patients. However, diagnostic misclassifications are common as it may be difficult to differentiate between IPAH and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). We investigated the hypothesis that the capillary pCO2 (pcCO2) may help distinguishing between idiopathic pulmonary arterial hypertension (IPAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). In a cross-sectional study, we retrospectively assessed pcCO2 levels (obtained from arterialized capillary blood at the time of diagnosis) from patients with IPAH or PH-HFpEF, respectively. Receiver operated characteristics (ROC) were used to determine the pcCO2 level providing the best discrimination between these two conditions. PcCO2 values were considered helpful if they were associated with a negative predictive value >0.9 to excluded either IPAH or PH-HFpEF. The study enrolled 185 patients, 99 with IPAH (74% female; age 47 ± 17 years; body mass index 26 ± 5 kg/m2, PAPm 53 ± 12 mmHg, PAWP 8 ± 3 mmHg), and 86 with PH-HFpEF (64% female; age 69 ± 10 years; body mass index 30 ± 6 kg/m2, PAPm 47 ± 10 mmHg, PAWP 21 ± 5 mmHg). PcCO2 at time of diagnosis was 33 ± 4 mmHg in the IPAH group and 40 ± 5 mmHg in the PH-HFpEF group (p < 0.001), respectively. According to ROC analysis, a pcCO2 of 36 mmHg was the best discriminator between both entities with an area under curve of 0.87 (p < 0.001). The likelihood of PH-HFpEF was <10% in patients with a PcCO2 < 34 mmHg, whereas the likelihood of IPAH was <10% in patients with a PcCO2 > 41 mmHg. PcCO2 levels were significantly lower in IPAH compared to PH-HFpEF and may provide useful information in differentiating between both conditions.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057352338

Download citation: RISBibTeXText

PMID: 25853979

DOI: 10.1186/s12931-015-0194-6


Related references

Comparison of Pulmonary Artery (PA) Wave Reflections in Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction (PH-HFpEF). Journal of Heart and Lung Transplantation 34(4): S118-S119, 2015

Pulmonary Arterial Reactivity in Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension Similar to Pulmonary Arterial Hypertension. Journal of Cardiac Failure 19(8): S3-S4, 2013

Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 198(5): 681-684, 2018

Heart Failure with Preserved Ejection Fraction Induced Reactive Pulmonary Hypertension Lacks Nitric Oxide Vasoreactivity Similar to Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation 33(4): S146-S147, 2014

Combined disease with pulmonary arterial hypertension and pulmonary venous hypertension revealed after treatment of heart failure with preserved ejection fraction in a case with primary Sjögren syndrome. Modern Rheumatology 28(1): 193-196, 2015

Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Failure Reviews 21(3): 285-297, 2018

In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction. Pulmonary Circulation 6(4): 551-556, 2017

Differentiating Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension from Pulmonary Hypertension Using Demographic Data and Common Blood Measurements. Journal of Heart and Lung Transplantation 33(4): S147-S148, 2014

Airway bypass stents for emphysema, algorithm to exclude precapillary pulmonary hypertension, and sildenafil for pulmonary hypertension in heart failure with preserved ejection fraction. American Journal of Respiratory and Critical Care Medicine 185(12): 1323-1324, 2012

Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging 19(4): 425-432, 2017

Treatment Of Pulmonary Arterial Hypertension Associated With Heart Failure With Preserved Ejection Fraction: A Pilot Study Of Ranolazine. Chest 144(4): 1022A-1022B, 2013

Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. International Journal of Cardiology 2019, 2019

Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation 137(17): 1796-1810, 2017

Pulmonary hemodynamics in heart failure patients with reduced or preserved ejection fraction and pulmonary hypertension: Similarities and disparities. American Heart Journal 192: 120-127, 2017

The other pulmonary hypertension: heart failure with preserved ejection fraction. International Journal of Clinical Practice. Suppl. 2012(172): 3-5, 2012